Meta AnalysisID 6287
常用口服中成药治疗骨质疏松的疗效与安全性：网状Meta分析
CRD42020168177
Randomized controlled trial. The subjects of this study are elderly osteoporosis patients, whose gender and race are not limited. The intervention measures were the same in the baseline treatment. The experimental group
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6287
- Evidence Id
- 14845
- Core Evidence Id
- 14845
- Source Meta Analysis Id
- 6271
- Herb2 Meta Analysis Id
- HBMA006271
- Crd Id
- CRD42020168177
- Title
- A network meta-analysis of the efficacy and safety of commonly used oral traditional Chinese patent medicine in the treatment of osteoporosis
- Review Question
- Randomized controlled trial. The subjects of this study are elderly osteoporosis patients, whose gender and race are not limited. The intervention measures were the same in the baseline treatment. The experimental group was treated with western medicine in combination with the commonly used oral Chinese patent medicine (such as jintiange capsule, Liuwei Dihuang pill, Gushukang, Qianggu Capsule, Gubao, Xianling Gubao capsule, Guli capsule, gushongbao, Jinwugutong capsule, Qing e pill, Zuogui pill). The control group was treated with western medicine. Outcome indicators: 1. Clinical efficiency; 2. Total BMD score comparison; 3. BMD score comparison of lumbar L2-4 site; 4. BMD score comparison of femoral neck site; 5. Score comparison of symptom improvement before and after treatment; 6. VAS scale comparison; 7. Serum index comparison (including blood calcium, blood phosphorus, alkaline phosphatase/AKP, osteocalcin/BGP and other indicators); 8. Adverse reactions. A variety of commonly used oral Chinese patent medicines have clinical comparability in the adjuvant treatment of osteoporosis, but their actual clinical efficacy is lack of evidence-based basis. Therefore, in this study, the network meta-analysis method is used to summarize the relevant indicators of these commonly used oral Chinese patent medicines and carry out quantitative statistical analysis, and then select the best oral Chinese patent medicine for clinical treatment, in order to provide clinical reference Provide reliable evidence-based medical evidence.
- Study Type Included
- The type of study was clinical randomized controlled trial (RCT). The subjects of the study were patients who were definitely diagnosed with osteoporosis, and there were no restrictions on the sex and race of these patients. The original literature should have a clear diagnosis standard of Western medicine or traditional Chinese medicine. It should conform to the relevant standards of the diagnosis and treatment guide for primary osteoporosis issued by the osteoporosis and bone mineral Disease Branch of the Chinese Medical Association, or the QCT diagnosis standard for osteoporosis of lumbar spine issued by the American College of Radiology (ACR), or according to the expert consensus on the diagnostic criteria of Chinese osteoporosis prepared by the osteoporosis and bone mineral Disease Branch of Chinese Medical Association and the diagnostic criteria of osteoporosis issued by the World Health Organization (WHO).
- Condition Being Studied
- Osteoporosis (OP) is a kind of degenerative bone disease, which is characterized by the decrease of bone mass and the degradation of bone microstructure, resulting in the increase of bone fragility and fracture. The main clinical manifestations of the disease are bone pain, hunchback, shortened body length, and the fall fracture problem caused by osteoporosis in severe cases. In addition, the recovery ability of the middle-aged and old people themselves slows down. Therefore, once the fracture occurs, the normal quality of life of the middle-aged and old people will be seriously affected. With the increase of the proportion of the elderly population and the increasing degree of social aging, the incidence and disability rate of the disease has been increasing year by year, which seriously affects the physical and mental health of patients.
- Participant
- The type of study was clinical randomized controlled trial (RCT). The subjects of the study were patients who were definitely diagnosed with osteoporosis, and there were no restrictions on the sex and race of these patients. The original literature should have a clear diagnosis standard of Western medicine or traditional Chinese medicine. It should conform to the relevant standards of the diagnosis and treatment guide for primary osteoporosis issued by the osteoporosis and bone mineral Disease Branch of the Chinese Medical Association, or the QCT diagnosis standard for osteoporosis of lumbar spine issued by the American College of Radiology (ACR), or according to the expert consensus on the diagnostic criteria of Chinese osteoporosis prepared by the osteoporosis and bone mineral Disease Branch of Chinese Medical Association and the diagnostic criteria of osteoporosis issued by the World Health Organization (WHO).
- Animal
- Human Disease Modelled
- Intervention
- The intervention measures were the same in the baseline treatment, the experimental group was treated with the commonly oral traditional Chinese patent medicine (such as jintiange capsule, Liuwei Dihuang pill, Gushukang, Qianggu Capsule, Gubao, Xianling Gubao capsule, Guli capsule, gushongbao, Jinwugutong capsule, Qinge pill, Zuogui pill) combined with western medicine.
- Comparator Control
- The control group was treated with western medicine. Western medicine was used as the control, and the dosage and method of Western medicine used in the control group were the same as those used in the experimental group.
- Main Outcome
- Outcome indicators: 1. Clinical efficiency; 2. Total BMD score comparison; 3. BMD score comparison of lumbar L2-4 site; 4. BMD score comparison of femoral neck site; 5. Score comparison of symptom improvement before and after treatment; 6. Vas scale comparison; 7. Serum index comparison (including blood calcium, blood phosphorus, alkaline phosphatase AKP, osteocalcin BGP and other indicators); 8. Adverse reactions. Measures of effect The treatment period is three to twelve months.
- Outcome Measure
- Additional Outcome
- Not applicable. Measures of effect Not applicable.
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Humans
- Contact
- Ying Yu [email protected]
- Organisational Affiliation
- Medical college http://www.sdutcm.edu.cn/
- Funding Source
- 1.Mechanism and efficacy evaluation of the first group of excellent scientific research and innovation teams of shandong university of traditional Chinese medicine（220316）2. 2016 key R & D plan of Shandong Province (key key technology and key industry key technology) (2016CYJS08A01-6) 3. 2017-2018 traditional Chinese medicine science and technology development plan project of Shandong Province (No.: 2017-018) 4. 2015-2016 traditional Chinese medicine science and technology development plan project of Shandong Province (No.: 2015-030) 5. 2018 Shandong university scientific research development plan project (J18KB130)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-02-06
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-12-31
- Anticipated Completion Date
- 2020-03-14
- Title Cn
- 常用口服中成药治疗骨质疏松的疗效与安全性：网状Meta分析
- Title En
- A network meta-analysis of the efficacy and safety of commonly used oral traditional Chinese patent medicine in the treatment of osteoporosis
- Bilingual Status
- complete